Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations —

— Facility provides potential for no scheduled interest or principal payments until maturity in December 2030 —